Barinthus Biotherapeutics
| Company type | Public |
|---|---|
| Nasdaq: BRNS | |
| Industry | |
| Founded | 2016 |
| Founders | |
| Headquarters | , United Kingdom |
| Website | barinthusbio |
Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.